The Value of Pentraxin-3 (PTX-3) as Clinical Marker in Diagnosis of Pediatric Community Acquired Pneumonia (CAP)
Sanad Arafa, R., Ata Sobeih, A., Shawky Abd Elhameed, H., Shehata El Dsouky Shehata, A. (2025). The Value of Pentraxin-3 (PTX-3) as Clinical Marker in Diagnosis of Pediatric Community Acquired Pneumonia (CAP). EKB Journal Management System, 42(4), 539-549. doi: 10.21608/bmfj.2024.332766.2243
Reda Sanad Arafa; Ahmad Ata Sobeih; Hasnaa Shawky Abd Elhameed; Abeer Shehata El Dsouky Shehata. "The Value of Pentraxin-3 (PTX-3) as Clinical Marker in Diagnosis of Pediatric Community Acquired Pneumonia (CAP)". EKB Journal Management System, 42, 4, 2025, 539-549. doi: 10.21608/bmfj.2024.332766.2243
Sanad Arafa, R., Ata Sobeih, A., Shawky Abd Elhameed, H., Shehata El Dsouky Shehata, A. (2025). 'The Value of Pentraxin-3 (PTX-3) as Clinical Marker in Diagnosis of Pediatric Community Acquired Pneumonia (CAP)', EKB Journal Management System, 42(4), pp. 539-549. doi: 10.21608/bmfj.2024.332766.2243
Sanad Arafa, R., Ata Sobeih, A., Shawky Abd Elhameed, H., Shehata El Dsouky Shehata, A. The Value of Pentraxin-3 (PTX-3) as Clinical Marker in Diagnosis of Pediatric Community Acquired Pneumonia (CAP). EKB Journal Management System, 2025; 42(4): 539-549. doi: 10.21608/bmfj.2024.332766.2243

The Value of Pentraxin-3 (PTX-3) as Clinical Marker in Diagnosis of Pediatric Community Acquired Pneumonia (CAP)

Benha Medical Journal
Article 18, Volume 42, Issue 4, April 2025, Page 539-549  XML PDF (744.8 K)
Document Type: Original Article
DOI: 10.21608/bmfj.2024.332766.2243
View on SCiNiTO View on SCiNiTO
Authors
Reda Sanad Arafa1; Ahmad Ata Sobeih1; Hasnaa Shawky Abd Elhameed2; Abeer Shehata El Dsouky Shehata email 3
1MD, Pediatrics department, Faculty of Medicine, Benha University, Benha, Egypt
2MD, Medical Microbiology & Immunology department, Faculty of Medicine, Benha University, Benha, Egypt
3M.B.B. Ch, Faculty of Medicine, Tanta University, Egypt
Abstract
Background: Community acquired pneumonia (CAP) is defined as the presence of signs and symptoms of pneumonia in a previously healthy child due to an infection which has been acquired outside hospital. This study aimed to evaluate the value of Pentraxin-3 (PTX-3) as a clinical marker in diagnosis of CAP in pediatrics and assessment of its severity. Methods: This cross-sectional study included 60 children, divided into 40 children with CAP and 20 age and sex-matched healthy controls. All patients underwent clinical and chest examination, laboratory investigations, and radiological examination. Results: The PTX3 levels showed statistically significant positive correlation with the WBCs count (r = 0.285, p = 0.027), neutrophils count (r = 0.259, p= 0.046), ESR (r = 0.486, p < 0.001), hospital stay length (r = 0.465, p = 0.003), CRP (r = 0.365, p = 0.004), and PCT (r = 0.372, p = 0.003). PTX3 level of 7.94 (ng/ml) wase able to differentiate patients with CAP from the control group with a sensitivity of 95% and a specificity of 95%. PTX3 had significantly higher diagnostic performance for discrimination of CAP cases compared to CRP (p =0.041) and PCT (0.03). Conclusion: PTX-3 emerges as a promising biomarker for CAP diagnosis and severity assessment, exhibiting potential advantages over conventional markers like CRP and PCT. The findings highlight the clinical utility of PTX-3 in discriminating CAP cases from controls with high sensitivity and specificity.
Keywords
PTX-3; Marker; Pediatric; Community Acquired Pneumonia
Statistics
Article View: 121
PDF Download: 91